+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The patient at risk of sudden death:value of drug therapy



The patient at risk of sudden death:value of drug therapy



Revista Portuguesa de Cardiologia 19(2): 233-239



The evaluation of antiarrhythmic therapy should be based on its effects on total mortality assessed by controlled trials. The author reviews the large trials on antiarrhythmic drugs, during the past ten years, and concludes with the current importance of such therapy. Trials have been conducted in three kinds of high-risk populations: patients with malignant ventricular arrhythmias, survivors of myocardial infarction and patients with congestive heart failure. The results have been disappointing, showing either an increase in mortality with antiarrhythmic drugs (class I, d-sotalol) or a neutral effect (amiodarone). Trials conducted in patients with malignant arrhythmias have shown that the implantable cardioverter-defibrillator was superior to the best available antiarrhythmic therapy. In other high-risk populations, the only drugs that consistently reduced mortality were betablockers, which might have other mechanisms of action besides the antiarrhythmic effect. Amiodarone, the most potent suppressor of ventricular arrhythmias, is indicated in highly symptomatic patients; dl-sotalol is a good alternative to amiodarone. We may conclude from these large trials that study endpoints must be correctly chosen in order to assess the real value of an antiarrhythmic drug. The study population must have a high risk of sudden death and be within an appropriate time window of maximal risk. Antiarrhythmic trials must proceed, learning the lessons from the old studies, trying to test new drugs or new therapeutic strategies, better selecting study populations and new risk markers superior to those currently available.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047696027

Download citation: RISBibTeXText

PMID: 10763353


Related references

Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death. Pharmacoeconomics 20(11): 727-738, 2002

ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection. Herzschrittmachertherapie and Elektrophysiologie 26(2): 75-81, 2015

Quantitative T-wave alternans analysis for sudden cardiac death risk assessment and guiding therapy: answered and unanswered questions: For: Proceedings of ICE2015 Comandatuba, Brazil, Sudden Death Symposium. Journal of Electrocardiology 49(3): 429-438, 2016

Antiarrhythmic drug therapy in 367 heart failure patients class i drugs but not amiodarone are associated with increased sudden death risk. Journal of the American College of Cardiology 17(2 Suppl. A): 92A, 1991

Sudden syncope in your patient. Harmless cardiovascular disorder or risk of sudden cardiac death?. Mmw Fortschritte der Medizin 142(23): 16-17, 2000

Identification by holter of patients at risk for recurrent sudden death or syncope despite abolition of hypotensive ventricular tachy cardia by drug therapy. Circulation Suppl. 62(3): III-84, 1980

Can electro physiologically guided drug therapy reduce the incidence of sudden death in high risk patients with nonsustained ventricular tachy cardia?. American Heart Association Monograph: Iii-380, 1983

Sudden cardiac death. Risk stratification and potential for reduction by drug therapy. Symposium, held at the Xth World Congress of Cardiology. Washington, D.C., September 18, 1986. Cardiology 74(Suppl. 2): 1-71, 1987

Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon Sudden Unexpected Death Study and the Atherosclerosis Risk in Communities Study. European Heart Journal 38(40): 3017-3025, 2017

Risk scoring systems for identification of infants at high risk of sudden infant death syndrome (SIDS) or sudden unexpected infant death (SUD). Paediatric and Perinatal Epidemiology 8(1): 1-9, 1994

Sudden death. Prevention and countermeasure of the sudden death. Prevention of the sudden death by antiarrhythmic drug treatment. Nihon Naika Gakkai Zasshi 87(1): 117-123, 1998

Sudden death. Actual condition of the sudden death and pathophysiology. Drug side effect. Nihon Naika Gakkai Zasshi 87(1): 63-71, 1998

The risk of sudden death in the coronary patient. Soins. Cardiologie 1984(12): 7, 1984

High risk for sudden death identified by electrocardiographic loop recording in a patient with hypertrophic cardiomyopathy without major risk factors. American Journal of Cardiology 107(10): 1558-1560, 2011

Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. American Journal of Cardiology 106(10): 1481-1486, 2010